|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ng KL: The Etiology of Prostate Cancer.
In: Prostate Cancer. Bott SRJ and Ng KL (eds). Exon Publications,
Brisbane, Queensland, 2021.
|
|
3
|
Sekhoacha M, Riet K, Motloung P, Gumenku
L, Adegoke A and Mashele S: Prostate cancer review: Genetics,
diagnosis, treatment options, and alternative approaches.
Molecules. 27(5730)2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Adamaki M and Zoumpourlis V: Prostate
cancer biomarkers: From diagnosis to prognosis and precision-guided
therapeutics. Pharmacol Ther. 228(107932)2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Cai C, Chen S, Ng P, Bubley GJ, Nelson PS,
Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, et al:
Intratumoral de novo steroid synthesis activates androgen receptor
in castration-resistant prostate cancer and is upregulated by
treatment with CYP17A1 inhibitors. Cancer Res. 71:6503–6513.
2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Hellmis E, Schwentner C, Mandel P, Banek
S, Gleissner J and Bogemann M: Apalutamide in patients with
high-risk M0CRPC: Data from the pivotal SPARTAN study and initial
experience from a compassionate use program. Aktuelle Urol.
54:140–147. 2023.PubMed/NCBI View Article : Google Scholar : (In German).
|
|
7
|
Rajaram P, Rivera A, Muthima K, Olveda N,
Muchalski H and Chen QH: Second-generation androgen receptor
antagonists as hormonal therapeutics for three forms of prostate
cancer. Molecules. 25(2448)2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Shen J, Chowdhury S, Agarwal N, Karsh LI,
Oudard S, Gartrell BA, Feyerabend S, Saad F, Pieczonka CM, Chi KN,
et al: Apalutamide efficacy, safety and wellbeing in older patients
with advanced prostate cancer from Phase 3 randomised clinical
studies TITAN and SPARTAN. Br J Cancer. 130:73–81. 2024.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ruiz de Porras V, Font A and Aytes A:
Chemotherapy in metastatic castration-resistant prostate cancer:
Current scenario and future perspectives. Cancer Lett. 523:162–169.
2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Scher HI, Lu D, Schreiber NA, Louw J, Graf
RP, Vargas HA, Johnson A, Jendrisak A, Bambury R, Danila D, et al:
Association of AR-V7 on circulating tumor cells as a
treatment-specific biomarker with outcomes and survival in
castration-resistant prostate cancer. JAMA Oncol. 2:1441–1449.
2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Deluce JE, Cardenas L, Lalani AK, Maleki
Vareki S and Fernandes R: Emerging Biomarker-guided therapies in
prostate cancer. Curr Oncol. 29:5054–5076. 2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Asif S and Teply BA: Biomarkers for
treatment response in advanced prostate cancer. Cancers (Basel).
13(5723)2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Singh P, Patel M, Bhowmik D, Kumari N,
Prajapati KS and Gupta R: Identification of common biomarkers
affecting patient survival in cancers. World Acad Sci. 6:1–12.
2024.
|
|
14
|
Patel M, Singh P, Gandupalli L and Reeshu
G: Identification and evaluation of Survival-associated common
chemoresistant genes in cancer. Biomed Biotechnol Res J. 8:320–327.
2024.
|
|
15
|
Chen JY, Wang PY, Liu MZ, Lyu F, Ma MW,
Ren XY and Gao XS: Biomarkers for prostate cancer: From diagnosis
to treatment. Diagnostics (Basel). 13(3350)2023.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Pires FR, Sagarra R, Corrêa ME, Pereira
CM, Vargas PA and Lopes MA: Oral metastasis of a hepatocellular
carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod.
97:359–368. 2004.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Sobhani N, Neeli PK, D'Angelo A, Pittacolo
M, Sirico M, Galli IC, Roviello G and Nesi G: AR-V7 in metastatic
prostate cancer: A strategy beyond redemption. Int J Mol Sci.
22(5515)2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hu R, Dunn TA, Wei S, Isharwal S, Veltri
RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, et al:
Ligand-independent androgen receptor variants derived from splicing
of cryptic exons signify hormone-refractory prostate cancer. Cancer
Res. 69:16–22. 2009.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Katleba KD, Ghosh PM and Mudryj M: Beyond
prostate cancer: An androgen receptor splice variant expression in
multiple malignancies, non-cancer pathologies, and development.
Biomedicines. 11(2215)2023.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ferguson DC, Mata DA, Tay TK, Traina TA,
Gucalp A, Chandarlapaty S, D'Alfonso TM, Brogi E, Mullaney K,
Ladanyi M, et al: Androgen receptor splice variant-7 in breast
cancer: Clinical and pathologic correlations. Mod Pathol.
35:396–402. 2022.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Lieberman AP and Robins DM: The androgen
receptor's CAG/glutamine tract in mouse models of neurological
disease and cancer. J Alzheimers Dis. 14:247–255. 2008.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Dauki AM, Blachly JS, Kautto EA, Ezzat S,
Abdel-Rahman MH and Coss CC: Transcriptionally active androgen
receptor splice variants promote hepatocellular carcinoma
progression. Cancer Res. 80:561–575. 2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Sharp A, Coleman I, Yuan W, Sprenger C,
Dolling D, Rodrigues DN, Russo JW, Figueiredo I, Bertan C, Seed G,
et al: Androgen receptor splice variant-7 expression emerges with
castration resistance in prostate cancer. J Clin Invest.
129:192–208. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Watson PA, Chen YF, Balbas MD, Wongvipat
J, Socci ND, Viale A, Kim K and Sawyers CL: Constitutively active
androgen receptor splice variants expressed in castration-resistant
prostate cancer require full-length androgen receptor. Proc Natl
Acad Sci USA. 107:16759–16765. 2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wang Z, Shen H, Liang Z, Mao Y, Wang C and
Xie L: The characteristics of androgen receptor splice variant 7 in
the treatment of hormonal sensitive prostate cancer: A systematic
review and meta-analysis. Cancer Cell Int. 20(149)2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
König P, Eckstein M, Jung R, Abdulrahman
A, Guzman J, Weigelt K, Serrero G, Hayashi J, Geppert C, Stöhr R,
et al: Expression of AR-V7 (androgen receptor variant 7) protein in
granular cytoplasmic structures is an independent prognostic factor
in prostate cancer patients. Cancers (Basel).
12(2639)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Hu R, Lu C, Mostaghel EA, Yegnasubramanian
S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E,
et al: Distinct transcriptional programs mediated by the
ligand-dependent full-length androgen receptor and its splice
variants in castration-resistant prostate cancer. Cancer Res.
72:3457–3462. 2012.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Bevan CL, Hoare S, Claessens F, Heery DM
and Parker MG: The AF1 and AF2 domains of the androgen receptor
interact with distinct regions of SRC1. Mol Cell Biol.
19:8383–8392. 1999.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Chen Z, Wu D, Thomas-Ahner JM, Lu C, Zhao
P, Zhang Q, Geraghty C, Yan PS, Hankey W, Sunkel B, et al: Diverse
AR-V7 cistromes in castration-resistant prostate cancer are
governed by HoxB13. Proc Natl Acad Sci USA. 115:6810–6815.
2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Dai C, Dehm SM and Sharifi N: Targeting
the androgen signaling axis in prostate cancer. J Clin Oncol.
41:4267–4278. 2023.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Mostaghel EA: Alternative acts: Oncogenic
splicing of steroidogenic enzymes in prostate cancer. Clin Cancer
Res. 25:1139–1141. 2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Henzler C, Li Y, Yang R, McBride T, Ho Y,
Sprenger C, Liu G, Coleman I, Lakely B, Li R, et al: Truncation and
constitutive activation of the androgen receptor by diverse genomic
rearrangements in prostate cancer. Nat Commun.
7(13668)2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Zhang T, Karsh LI, Nissenblatt MJ and
Canfield SE: Androgen receptor splice variant, AR-V7, as a
biomarker of resistance to androgen Axis-targeted therapies in
advanced prostate cancer. Clin Genitourin Cancer. 18:1–10.
2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Liu C, Armstrong CM, Lou W, Lombard AP,
Cucchiara V, Gu X, Yang JC, Nadiminty N, Pan CX, Evans CP, et al:
Niclosamide and bicalutamide combination treatment overcomes
Enzalutamide- and bicalutamide-resistant prostate cancer. Mol
Cancer Ther. 16:1521–1530. 2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Antonarakis ES, Lu C, Luber B, Wang H,
Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA,
et al: Androgen receptor splice variant 7 and efficacy of taxane
chemotherapy in patients with metastatic castration-resistant
prostate cancer. JAMA Oncol. 1:582–591. 2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Antonarakis ES, Lu C, Luber B, Wang H,
Chen Y, Zhu Y, ilberstein JL, Taylor MN, Maughan BL, Denmeade SR,
et al: Clinical significance of androgen receptor splice variant-7
mRNA detection in circulating tumor cells of men with metastatic
castration-resistant prostate cancer treated with First- and
Second-line abiraterone and enzalutamide. J Clin Oncol.
35:2149–2156. 2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Kono M, Fujii T, Lim B, Karuturi MS,
Tripathy D and Ueno NT: Androgen receptor function and androgen
Receptor-targeted therapies in breast cancer: A review. JAMA Oncol.
3:1266–1273. 2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Gatalica Z, Hoag J, Hall DW, Alyaqoub FS,
Dombrowski S, Noel P, Szelinger S, Udhane S, Min W and Thakkar SG:
CGE23-072: The frequency of androgen receptor splice Variant 7
(AR-V7) in solid tumors. J Nat Comprehensive Nat Netw. 21:2023.
|
|
39
|
Armstrong AJ, Halabi S, Luo J, Nanus DM,
Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Rothwell
CJ, et al: Prospective multicenter validation of androgen receptor
splice variant 7 and hormone therapy resistance in High-risk
Castration-resistant prostate cancer: The PROPHECY Study. J Clin
Oncol. 37:1120–1129. 2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Carles J, Alonso-Gordoa T, Mellado B,
Mendez-Vidal MJ, Vazquez S, Gonzalez-Del-Alba A, Piulats JM,
Borrega P, Gallardo E, Morales-Barrera R, et al: Radium-223 for
patients with metastatic castration-resistant prostate cancer with
asymptomatic bone metastases progressing on first-line abiraterone
acetate or enzalutamide: A single-arm phase II trial. Eur J Cancer.
173:317–3126. 2022.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Shenderov E, Boudadi K, Fu W, Wang H,
Sullivan R, Jordan A, Dowling D, Harb R, Schonhoft J, Jendrisak A,
et al: Nivolumab plus ipilimumab, with or without enzalutamide, in
AR-V7-expressing metastatic castration-resistant prostate cancer: A
phase-2 nonrandomized clinical trial. Prostate. 81:326–338.
2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Tewari A: AMG 160 aH-LE, PSMA-Targeted,
Bispecific T-cell Engager (BiTE®) immune Therapy for
mCRPC-Interim Results From a Phase I Study. [(Accessed on 30 April
2021)]; Available online: https://www.urotoday.com/conference-highlights/esmo-2020/prostate-cancer/124632-esmo-virtual-congress-2020-amg-160-a-half-life-extended-psma-targeted-bispecific-t-cell-engager-bite-immune-therapy-for-mcrpc-interim-results-from-a-phase-i-study.html.
|
|
43
|
Li W, Zhang B, Tang J, Cao Q, Wu Y, Wu C,
Guo J, Ling EA and Liang F: Sirtuin 2, a mammalian homolog of yeast
silent information regulator-2 longevity regulator, is an
oligodendroglial protein that decelerates cell differentiation
through deacetylating alpha-tubulin. J Neurosci. 27:2606–2616.
2007.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Rana Z, Diermeier S, Hanif M and Rosengren
RJ: Understanding failure and improving treatment using HDAC
inhibitors for prostate cancer. Biomedicines. 8(22)2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Eckschlager T, Plch J, Stiborova M and
Hrabeta J: Histone deacetylase inhibitors as anticancer drugs. Int
J Mol Sci. 18(1414)2017.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Oehme I, Deubzer HE, Wegener D, Pickert D,
Linke JP, Hero B, Kopp-Schneider A, Westermann F, Ulrich SM, von
Deimling A, et al: Histone deacetylase 8 in neuroblastoma
tumorigenesis. Clin Cancer Res. 15:91–99. 2009.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Wang L, Zou X, Berger AD, Twiss C, Peng Y,
Li Y, Chiu J, Guo H, Satagopan J, Wilton A, et al: Increased
expression of histone deacetylaces (HDACs) and inhibition of
prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J
Transl Res. 1:62–71. 2009.PubMed/NCBI
|
|
48
|
Weichert W, Roske A, Gekeler V, Beckers T,
Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M,
et al: Histone deacetylases 1, 2 and 3 are highly expressed in
prostate cancer and HDAC2 expression is associated with shorter PSA
relapse time after radical prostatectomy. Br J Cancer. 98:604–610.
2008.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Shankar E, Pandey M, Verma S, Abbas A,
Candamo M, Kanwal R, Shukla S, MacLennan GT and Gupta S: Role of
class I histone deacetylases in the regulation of maspin expression
in prostate cancer. Mol Carcinog. 59:955–966. 2020.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Waltregny D, North B, Van Mellaert F, de
Leval J, Verdin E and Castronovo V: Screening of histone
deacetylases (HDAC) expression in human prostate cancer reveals
distinct class I HDAC profiles between epithelial and stromal
cells. Eur J Histochem. 48:273–290. 2004.PubMed/NCBI
|
|
51
|
Li Y and Seto E: HDACs and HDAC inhibitors
in cancer development and therapy. Cold Spring Harb Perspect Med.
6(a026831)2016.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Zeng LS, Yang XZ, Wen YF, Mail SJ, Wang
MH, Zhang MY, Zheng XF and Wang HY: Overexpressed HDAC4 is
associated with poor survival and promotes tumor progression in
esophageal carcinoma. Aging (Albany NY). 8:1236–1249.
2016.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Beaver LM, Lӧhr CV, Clarke JD, Glasser ST,
Watson GW, Wong CP, Zhang Z, Williams DE, Dashwood RH, Shannon J,
et al: Broccoli sprouts delay prostate cancer formation and
decrease prostate cancer severity with a concurrent decrease in
HDAC3 protein expression in transgenic adenocarcinoma of the mouse
prostate (TRAMP) mice. Curr Dev Nutr. 2(nzy002)2018.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Jang YG, Hwang KA and Choi KC: Rosmarinic
acid, a component of rosemary tea, induced the cell cycle arrest
and apoptosis through modulation of HDAC2 expression in prostate
cancer cell lines. Nutrients. 10(1784)2018.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Pandey M, Kaur P, Shukla S, Abbas A, Fu P
and Gupta S: Plant flavone apigenin inhibits HDAC and remodels
chromatin to induce growth arrest and apoptosis in human prostate
cancer cells: In vitro and in vivo study. Mol Carcinog. 51:952–962.
2012.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Zhang L, Zhang J, Jiang Q, Zhang L and
Song W: Zinc binding groups for histone deacetylase inhibitors. J
Enzyme Inhib Med Chem. 33:714–721. 2018.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Yue K, Qin M, Huang C, James Chou C, Jiang
Y and Li X: Comparison of three zinc binding groups for HDAC
inhibitors-A potency, selectivity and enzymatic kinetics study.
Bioorg Med Chem Lett. 70(128797)2022.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Moi D, Bonanni D, Belluti S, Linciano P,
Citarella A, Franchini S, Sorbi C, Imbriano C, Pinzi L and Rastelli
G: Discovery of potent pyrrolo-pyrimidine and purine HDAC
inhibitors for the treatment of advanced prostate cancer. Eur J Med
Chem. 260(115730)2023.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Eigl BJ, North S, Winquist E, Finch D,
Wood L, Sridhar SS, Powers J, Good J, Sharma M, Squire JA, et al: A
phase II study of the HDAC inhibitor SB939 in patients with
castration resistant prostate cancer: NCIC clinical trials group
study IND195. Invest New Drugs. 33:969–976. 2015.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Ferrari AC, Alumkal JJ, Stein MN, Taplin
ME, Babb J, Barnett ES, Gomez-Pinillos A, Liu X, Moore D, DiPaola R
and Beer TM: Epigenetic therapy with panobinostat combined with
bicalutamide rechallenge in castration-resistant prostate cancer.
Clin Cancer Res. 25:52–63. 2019.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Biersack B, Nitzsche B and Hopfner M: HDAC
inhibitors with potential to overcome drug resistance in
castration-resistant prostate cancer. Cancer Drug Resist. 5:64–79.
2022.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Chen Z, Wang X, Yang X, Xu Y, Yang Y, Wang
H, Li T, Bai P, Yuan G, Chen H, et al: Imaging assisted evaluation
of antitumor efficacy of a new histone deacetylase inhibitor in the
castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging.
48:53–66. 2021.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Rosati R, Chen B, Patki M, McFall T, Ou S,
Heath E, Ratnam M and Qin Z: Hybrid Enzalutamide derivatives with
histone deacetylase inhibitor activity decrease heat shock protein
90 and androgen receptor levels and inhibit viability in
Enzalutamide-resistant C4-2 prostate cancer cells. Mol Pharmacol.
90:225–237. 2016.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Hu WY, Xu L, Chen B, Ou S, Muzzarelli KM,
Hu DP, Li Y, Yang Z, Vander Griend DJ, Prins GS and Qin Z:
Targeting prostate cancer cells with enzalutamide-HDAC inhibitor
hybrid drug 2-75. Prostate. 79:1166–1179. 2019.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Sun H, Mediwala SN, Szafran AT, Mancini MA
and Marcelli M: CUDC-101, a novel inhibitor of Full-length androgen
receptor (flAR) and androgen receptor variant 7 (AR-V7) activity:
Mechanism of action and in vivo efficacy. Horm Cancer. 7:196–210.
2016.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Lai CJ, Bao R, Tao X, Wang J, Atoyan R, Qu
H, Wang DG, Yin L, Samson M, Forrester J, et al: CUDC-101, a
multitargeted inhibitor of histone deacetylase, epidermal growth
factor receptor, and human epidermal growth factor receptor 2,
exerts potent anticancer activity. Cancer Res. 70:3647–3656.
2010.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Li X, Kamenecka TM and Cameron MD:
Cytochrome P450-mediated bioactivation of the epidermal growth
factor receptor inhibitor erlotinib to a reactive electrophile.
Drug Metab Dispos. 38:1238–1245. 2010.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Goehringer N, Biersack B, Peng Y, Schobert
R, Herling M, Ma A, Nitzsche B and Höpfner M: Anticancer activity
and mechanisms of action of new chimeric EGFR/HDAC-inhibitors. Int
J Mol Sci. 22(8432)2021.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Hu C, Xia H, Bai S, Zhao J, Edwards H, Li
X, Yang Y, Lyu J, Wang G, Zhan Y, et al: CUDC-907, a novel dual
PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity
and molecular mechanism of action. J Cell Mol Med. 24:7239–7253.
2020.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Wu CP, Hsieh YJ, Hsiao SH, Su CY, Li YQ,
Huang YH, Huang CW, Hsieh CH, Yu JS and Wu YS: Human ATP-binding
cassette transporter ABCG2 confers resistance to CUDC-907, a dual
inhibitor of histone deacetylase and phosphatidylinositol 3-Kinase.
Mol Pharm. 13:784–794. 2016.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Evans LW and Ferguson BS: Food bioactive
HDAC inhibitors in the epigenetic regulation of heart failure.
Nutrients. 10(1120)2018.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Lauri C, Chiurchioni L, Russo VM, Zannini
L and Signore A: PSMA expression in solid tumors beyond the
prostate gland: Ready for theranostic applications? J Clin Med.
11(6590)2022.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Uijen MJM, Derks YHW, Merkx RIJ, Schilham
MGM, Roosen J, Prive BM, van Lith SAM, van Herpen CML, Gotthardt M,
Heskamp S, et al: PSMA radioligand therapy for solid tumors other
than prostate cancer: Background, opportunities, challenges, and
first clinical reports. Eur J Nucl Med Mol Imaging. 48:4350–4368.
2021.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Kasperzyk JL, Finn SP, Flavin R,
Fiorentino M, Lis R, Hendrickson WK, Clinton SK, Sesso HD,
Giovannucci EL, Stampfer MJ, et al: Prostate-specific membrane
antigen protein expression in tumor tissue and risk of lethal
prostate cancer. Cancer Epidemiol Biomarkers Prev. 22:2354–2363.
2013.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Heskamp S, Hernandez R, Molkenboer-Kuenen
JDM, Essler M, Bruchertseifer F, Morgenstern A, Steenbergen EJ, Cai
W, Seidl C, McBride WJ, et al: α-versus β-emitting radionuclides
for pretargeted radioimmunotherapy of carcinoembryonic
antigen-expressing human colon cancer xenografts. J Nucl Med.
58:926–933. 2017.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Sheehan B, Guo C, Neeb A, Paschalis A,
Sandhu S and de Bono JS: Prostate-specific membrane antigen biology
in lethal prostate cancer and its therapeutic implications. Eur
Urol Focus. 8:1157–1168. 2022.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Zacherl MJ, Gildehaus FJ, Mittlmeier L,
Boning G, Gosewisch A, Wenter V, Unterrainer M, Schmidt-Hegemann N,
Belka C, Kretschmer A, et al: First clinical results for
PSMA-Targeted α-therapy using 225Ac-PSMA-I&T in Advanced-mCRPC
patients. J Nucl Med. 62:669–674. 2021.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Sathekge M, Bruchertseifer F, Knoesen O,
Reyneke F, Lawal I, Lengana T, Davis C, Mahapane J, Corbett C,
Vorster M and Morgenstern A: 225Ac-PSMA-617 in chemotherapy-naive
patients with advanced prostate cancer: A pilot study. Eur J Nucl
Med Mol Imaging. 46:129–138. 2019.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Tagawa ST, Thomas C, Sartor AO, Sun M,
Stangl-Kremser J, Bissassar M, Vallabhajosula S, Huicochea
Castellanos S, Nauseef JT, Sternberg CN, et al: Prostate-specific
membrane antigen-targeting alpha emitter via antibody delivery for
metastatic castration-resistant prostate cancer: A phase I
dose-escalation study of 225Ac-J591. J Clin Oncol. 42:842–581.
2024.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Baum RP, Kulkarni HR, Schuchardt C, Singh
A, Wirtz M, Wiessalla S, Schottelius M, Mueller D, Klette I and
Wester HJ: 177Lu-Labeled Prostate-specific membrane antigen
radioligand therapy of metastatic castration-resistant prostate
cancer: Safety and efficacy. J Nucl Med. 57:1006–1013.
2016.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Sandhu S, Joshua AM, Emmett L, Spain LA,
Horvath L, Crumbaker M, Anton A and Hofman MS: PRINCE: Phase I
trial of 177Lu-PSMA-617 in combination with pembrolizumab in
patients with metastatic castration-resistant prostate cancer
(mCRPC). J Clin Oncol. 40(5017)2022.
|
|
82
|
Dorff T, Horvath LG, Autio K,
Bernard-Tessier A, Rettig MB, Machiels JP, Bilen MA, Lolkema MP,
Adra N, Rottey S, et al: A phase I study of acapatamab, a Half-life
extended, PSMA-targeting bispecific T-cell engager for metastatic
castration-resistant prostate cancer. Clin Cancer Res.
30:1488–1500. 2024.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Hummel HD, Kufer P, Grullich C,
Seggewiss-Bernhardt R, Deschler-Baier B, Chatterjee M, Goebeler ME,
Miller K, de Santis M, Loidl W, et al: Pasotuxizumab, a
BiTE® immune therapy for castration-resistant prostate
cancer: Phase I, dose-escalation study findings. Immunotherapy.
13:125–141. 2021.PubMed/NCBI View Article : Google Scholar
|
|
84
|
De Bono JS, Fong L, Beer TM, Gao X,
Geynisman DM, Burris III HA, Strauss JF, Courtney KD, Quinn DI,
VanderWeele DJ, et al: Results of an ongoing phase 1/2a dose
escalation study of HPN424, a tri-specific half-life extended
PSMA-targeting T-cell engager, in patients with metastatic
castration-resistant prostate cancer (mCRPC). J Clin Oncol.
39(5013)2021.
|
|
85
|
Sandhu S, Joshua AM, Emmett L, Crumbaker
M, Bressel M, Huynh R, Banks PD, Wallace R, Hamid A, Inderjeeth AJ,
et al: LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in
patients with metastatic castration resistant prostate cancer
(mCRPC). J Clin Oncol. 41(5005)2023.
|
|
86
|
Xiao X, Lao XM, Chen MM, Liu RX, Wei Y,
Ouyang FZ, Chen DP, Zhao XY, Zhao Q, Li XF, et al: PD-1hi
identifies a novel regulatory B-cell population in human hepatoma
that promotes disease progression. Cancer Discov. 6:546–559.
2016.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Salvi S, Fontana V, Boccardo S, Merlo DF,
Margallo E, Laurent S, Morabito A, Rijavec E, Dal Bello MG, Mora M,
et al: Evaluation of CTLA-4 expression and relevance as a novel
prognostic factor in patients with non-small cell lung cancer.
Cancer Immunol Immunother. 61:1463–1472. 2012.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Seidel JA, Otsuka A and Kabashima K:
Anti-PD-1 and Anti-CTLA-4 therapies in cancer: Mechanisms of
action, efficacy, and limitations. Front Oncol.
8(86)2018.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Kwon ED, Drake CG, Scher HI, Fizazi K,
Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R,
Mahammedi H, et al: Ipilimumab versus placebo after radiotherapy in
patients with metastatic castration-resistant prostate cancer that
had progressed after docetaxel chemotherapy (CA184-043): A
multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol.
15:700–712. 2014.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Powles T, Yuen KC, Gillessen S, Kadel EE
III, Rathkopf D, Matsubara N, Drake CG, Fizazi K, Piulats JM,
Wysocki PJ, et al: Atezolizumab with enzalutamide versus
enzalutamide alone in metastatic castration-resistant prostate
cancer: A randomized phase 3 trial. Nat Med. 28:144–153.
2022.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Sharma P, Pachynski RK, Narayan V, Flechon
A, Gravis G, Galsky MD, Mahammedi H, Patnaik A, Subudhi SK,
Ciprotti M, et al: Initial results from a phase II study of
nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of
metastatic castration-resistant prostate cancer (mCRPC; CheckMate
650). J Clin Oncol. 37(142)2019.
|
|
92
|
Beer TM, Kwon ED, Drake CG, Fizazi K,
Logothetis C, Gravis G, Ganju V, Polikoff J, Saad F, Humanski P, et
al: Randomized, double-blind, phase III trial of ipilimumab versus
placebo in asymptomatic or minimally symptomatic patients with
metastatic Chemotherapy-naive castration-resistant prostate cancer.
J Clin Oncol. 35:40–47. 2017.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Hansen AR, Massard C, Ott PA, Haas NB,
Lopez JS, Ejadi S, Wallmark JM, Keam B, Delord JP, Aggarwal R, et
al: Pembrolizumab for advanced prostate adenocarcinoma: Findings of
the KEYNOTE-028 study. Ann Oncol. 29:1807–1813. 2018.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Antonarakis ES, Piulats JM, Gross-Goupil
M, Goh JC, Vaishampayan UN, De Wit R, Alanko T, Fukasawa S, Tabata
K, Feyerabend S, et al: Update on KEYNOTE-199, cohorts 1-3:
Pembrolizumab (pembro) for docetaxel-pretreated metastatic
castration-resistant prostate cancer (mCRPC). J Clin Oncol.
38(104)2020.
|
|
95
|
Hoimes CJ, Graff JN, Tagawa ST, Hwang C,
Kilari D, Tije AJT, Omlin A, McDermott RS, Vaishampayan UN, Elliott
T, et al: KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of
pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant
metastatic castration-resistant prostate cancer (mCRPC). J Clin
Oncol. 38(5543)2020.
|
|
96
|
Yu EY, Piulats JM, Gravis G, Laguerre B,
Arija JAA, Oudard S, Fong PCC, Kolinsky MP, Augustin M, Feyerabend
S, et al: KEYNOTE-365 cohort A updated results: Pembrolizumab
(pembro) plus olaparib in docetaxel-pretreated patients (pts) with
metastatic castration-resistant prostate cancer (mCRPC). J Clin
Oncol. 38(100)2020.
|
|
97
|
Berry WR, Fong PCC, Piulats JM, Appleman
LJ, Conter HJ, Feyerabend S, Shore ND, Gravis G, Laguerre B, Gurney
H, et al: KEYNOTE-365 cohort C updated results: Pembrolizumab
(pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated
patients (pts) with metastatic castrate-resistant prostate cancer
(mCRPC). J Clin Oncol. 38(102)2020.
|
|
98
|
Stein M, Fong L, Tutrone R, Mega A, Lam
ET, Vangala S, Dennie J, Petit R, Gutierrez A, Hayes S and Haas N:
KEYNOTE-046: Effects of ADXS-PSA with or without pembrolizumab on
survival and antigen spreading in metastatic, castration-resistant
prostate cancer patients. Cancer Res. 79(CT098)2019.
|
|
99
|
van den Eertwegh AJ, Versluis J, van den
Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, Gall
HE, Harding TC, Jooss K, Lowy I, et al: Combined immunotherapy with
granulocyte-macrophage colony-stimulating factor-transduced
allogeneic prostate cancer cells and ipilimumab in patients with
metastatic castration-resistant prostate cancer: A phase 1
dose-escalation trial. Lancet Oncol. 13:509–517. 2012.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Ross AE, Hurley PJ, Tran PT, Rowe SP,
Benzon B, Neal TO, Chapman C, Harb R, Milman Y, Trock BJ, et al: A
pilot trial of pembrolizumab plus prostatic cryotherapy for men
with newly diagnosed oligometastatic hormone-sensitive prostate
cancer. Prostate Cancer Prostatic Dis. 23:184–193. 2020.PubMed/NCBI View Article : Google Scholar
|
|
101
|
van Wilpe S, Kloots ISH, Slootbeek PHJ,
den Brok M, Westdorp H, Franken MD, Coskunturk M, Osinga T,
Bloemendal H, Adema G, et al: Ipilimumab with nivolumab in
molecularly selected patients with castration-resistant prostate
cancer: Primary analysis of the phase II INSPIRE trial. Ann Oncol.
35:1126–1137. 2024.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Wang XH, Wang ZQ, Mu ZY, Zhu LP, Zhong CF
and Guo S: The efficacy and safety of immune checkpoint inhibitors
in metastatic castration-resistant prostate cancer: A systematic
review and meta-analysis. Medicine (Baltimore).
101(e29715)2022.PubMed/NCBI View Article : Google Scholar
|
|
103
|
McNeel DG, Eickhoff JC, Wargowski E, Zahm
C, Staab MJ, Straus J and Liu G: Concurrent, but not sequential,
PD-1 blockade with a DNA vaccine elicits anti-tumor responses in
patients with metastatic, castration-resistant prostate cancer.
Oncotarget. 9:25586–25596. 2018.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Madan RA, Mohebtash M, Arlen PM, Vergati
M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL,
Wright JJ, et al: Ipilimumab and a poxviral vaccine targeting
prostate-specific antigen in metastatic castration-resistant
prostate cancer: A phase 1 dose-escalation trial. Lancet Oncol.
13:501–508. 2012.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Brahmer JR, Drake CG, Wollner I, Powderly
JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller
TL, et al: Phase I study of single-agent anti-programmed death-1
(MDX-1106) in refractory solid tumors: Aafety, clinical activity,
pharmacodynamics, and immunologic correlates. J Clin Oncol.
28:3167–3175. 2010.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Aguiar PN Jr, Santoro IL, Tadokoro H, de
Lima Lopes G, Filardi BA, Oliveira P, Mountzios G and de Mello RA:
The role of PD-L1 expression as a predictive biomarker in advanced
non-small-cell lung cancer: A network meta-analysis. Immunotherapy.
8:479–488. 2016.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Karja V, Aaltomaa S, Lipponen P, Isotalo
T, Talja M and Mokka R: Tumour-infiltrating lymphocytes: A
prognostic factor of PSA-free survival in patients with local
prostate carcinoma treated by radical prostatectomy. Anticancer
Res. 25:4435–4438. 2005.PubMed/NCBI
|
|
108
|
Ness N, Andersen S, Valkov A, Nordby Y,
Donnem T, Al-Saad S, Busund LT, Bremnes RM and Richardsen E:
Infiltration of CD8+ lymphocytes is an independent prognostic
factor of biochemical failure-free survival in prostate cancer.
Prostate. 74:1452–1461. 2014.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Sorrentino C, Musiani P, Pompa P,
Cipollone G and Di Carlo E: Androgen deprivation boosts prostatic
infiltration of cytotoxic and regulatory T lymphocytes and has no
effect on disease-free survival in prostate cancer patients. Clin
Cancer Res. 17:1571–1581. 2011.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Jiao S, Subudhi SK, Aparicio A, Ge Z, Guan
B, Miura Y and Sharma P: Differences in tumor microenvironment
dictate T helper lineage polarization and response to immune
checkpoint therapy. Cell. 179:1177–1190.e13. 2019.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Claps M, Mennitto A, Guadalupi V, Sepe P,
Stellato M, Zattarin E, Gillessen SS, Sternberg CN, Berruti A, De
Braud FGM, et al: Immune-checkpoint inhibitors and metastatic
prostate cancer therapy: Learning by making mistakes. Cancer Treat
Rev. 88(102057)2020.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Valabrega G, Scotto G, Tuninetti V, Pani A
and Scaglione F: Differences in PARP inhibitors for the treatment
of ovarian cancer: Mechanisms of action, pharmacology, safety, and
efficacy. Int J Mol Sci. 22(4203)2021.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Chan CY, Tan KV and Cornelissen B: PARP
inhibitors in cancer diagnosis and therapy. Clin Cancer Res.
27:1585–1594. 2021.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Thiery-Vuillemin A, de Bono J, Hussain M,
Roubaud G, Procopio G, Shore N, Fizazi K, Dos Anjos G, Gravis G,
Joung JY, et al: Pain and health-related quality of life with
olaparib versus physician's choice of next-generation hormonal drug
in patients with metastatic castration-resistant prostate cancer
with homologous recombination repair gene alterations (PROfound):
An open-label, randomised, phase 3 trial. Lancet Oncol. 23:393–405.
2022.PubMed/NCBI View Article : Google Scholar
|
|
115
|
de Bono J, Mateo J, Fizazi K, Saad F,
Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, et al:
Olaparib for metastatic castration-resistant prostate cancer. N
Engl J Med. 382:2091–2102. 2020.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Thiery-Vuillemin A, Oya M, Procopio G, De
Menezes JJ, Colagiovanni Girotto G, Ghatalia P, Nole F, Din O,
Spiegelhalder P, Mincik I, et al: Olaparib plus abiraterone as
first-line therapy in men with metastatic castration-resistant
prostate cancer: Pharmacokinetics data from the PROpel trial. J
Clin Oncol. 40(5050)2022.
|
|
117
|
Thiery-Vuillemin ASF, Saad F, Armstrong
AJ, Oya M, Maia Vianna KC, Özgüroğlu M, Gedye C, Buchschacher GL,
Lee JY, Emmenegger U, et al: Tolerability of abiraterone (abi)
combined with olaparib (ola) in patients (pts) with metastatic
castration-resistant prostate cancer (mCRPC): Further results from
the phase III PROpel trial. J Clin Oncol. 40(5019)2022.
|
|
118
|
Chen X, Pan Y, Wang Q, Ren C, Li M, Hao X
and Liu X: Comparative efficacy of olaparib in combination with or
without novel antiandrogens for treating metastatic
castration-resistant prostate cancer. Front Endocrinol (Lausanne).
14(1225033)2023.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Abida W, Patnaik A, Campbell D, Shapiro J,
Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E,
et al: Rucaparib in men with metastatic castration-resistant
prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin
Oncol. 38:3763–3772. 2020.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Abida W, Campbell D, Patnaik A, Shapiro
JD, Sautois B, Vogelzang NJ, Voog EG, Bryce AH, McDermott R, Ricci
F, et al: Non-BRCA DNA damage repair gene alterations and response
to the PARP inhibitor rucaparib in metastatic castration-resistant
prostate cancer: Analysis from the phase II TRITON2 study. Clin
Cancer Res. 26:2487–2496. 2020.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Rao A, Morris D, Assikis VJ, Gopalji Jha
G, Ryan CJ, Ablaza JA, Habeck J, Loehr A, Xiao J, Gangolli EA, et
al: Rucaparib plus enzalutamide in patients (pts) with metastatic
castration-resistant prostate cancer (mCRPC): Pharmacokinetics (PK)
and safety data from the phase Ib RAMP study. J Clin Oncol.
39(79)2021.
|
|
122
|
Smith MR, Scher HI, Sandhu S, Efstathiou
E, Lara PN Jr, Yu EY, George DJ, Chi KN, Saad F, Ståhl O, et al:
Niraparib in patients with metastatic castration-resistant prostate
cancer and DNA repair gene defects (GALAHAD): A multicentre,
open-label, phase 2 trial. Lancet Oncol. 23:362–373.
2022.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Chi KN, Rathkopf DE, Raymond Smith M,
Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Juliana Gomes A,
Roubaud G, et al: Phase 3 MAGNITUDE study: First results of
niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as
first-line therapy in patients (pts) with metastatic
castration-resistant prostate cancer (mCRPC) with and without
homologous recombination repair (HRR) gene alterations. J Clin
Oncol. 40(12)2022.
|
|
124
|
Agarwal N, Azad A, Shore ND, Carles J, Fay
AP, Dunshee C, Karsh LI, Paccagnella ML, Santo ND, Elmeliegy M, et
al: Talazoparib plus enzalutamide in metastatic
castration-resistant prostate cancer: TALAPRO-2 phase III study
design. Future Oncol. 18:425–436. 2022.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Karzai F, VanderWeele D, Madan RA, Owens
H, Cordes LM, Hankin A, Couvillon A, Nichols E, Bilusic M, Beshiri
ML, et al: Activity of durvalumab plus olaparib in metastatic
castration-resistant prostate cancer in men with and without DNA
damage repair mutations. J Immunother Cancer. 6(141)2018.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Yu E, Piulats JM, Gravis G, Fong P,
Todenhöfer T, Laguerre B, Arranz J, Oudard S, Massard C, Stoeckle
M, et al: 73P Association between homologous recombination repair
mutations and response to pembrolizumab (pembro) plus olaparib
(ola) in metastatic castration-resistant prostate cancer (mCRPC):
KEYNOTE-365 Cohort A biomarker analysis. Ann Oncol. 32
(Suppl)(S387)2021.
|
|
127
|
Robinson D, Van Allen EM, Wu YM, Schultz
N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC,
Attard G, et al: Integrative clinical genomics of advanced prostate
cancer. Cell. 161:1215–1228. 2015.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Carver BS, Chapinski C, Wongvipat J,
Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J,
Scher H, et al: Reciprocal feedback regulation of PI3K and androgen
receptor signaling in PTEN-deficient prostate cancer. Cancer Cell.
19:575–586. 2011.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Sirico M, D'Angelo A, Gianni C, Casadei C,
Merloni F and De Giorgi U: Current state and future challenges for
PI3K inhibitors in cancer therapy. Cancers (Basel).
15(703)2023.PubMed/NCBI View Article : Google Scholar
|
|
130
|
Sweeney C, Bracarda S, Sternberg CN, Chi
KN, Olmos D, Sandhu S, Massard C, Matsubara N, Alekseev B, Parnis
F, et al: Ipatasertib plus abiraterone and prednisolone in
metastatic castration-resistant prostate cancer (IPATential150): A
multicentre, randomised, double-blind, phase 3 trial. Lancet.
398:131–142. 2021.PubMed/NCBI View Article : Google Scholar
|
|
131
|
Sarker D, Dawson NA, Aparicio AM, Dorff
TB, Pantuck AJ, Vaishampayan UN, Henson L, Vasist L, Roy-Ghanta S,
Gorczyca M, et al: A Phase I, Open-label, Dose-finding study of
GSK2636771, a PI3Kβ inhibitor, administered with enzalutamide in
patients with metastatic castration-resistant prostate cancer. Clin
Cancer Res. 27:5248–5257. 2021.PubMed/NCBI View Article : Google Scholar
|
|
132
|
Pacey S, Shah N, Daviesbr BR, Bratt O,
Warren A, Davies RD, Gnanapragasam VJ, Ingle S, Stearn S, Machin A,
et al: A pharmacodynamic biomarker study of vistusertib (AZD2014),
an mTORC1/2 inhibitor, given prior to radical prostatectomy
(CANCAP02). J Clin Oncol. 36(5801)2018.
|
|
133
|
Graham L, Banda K, Torres A, Carver BS,
Chen Y, Pisano K, Shelkey G, Curley T, Scher HI, Lotan TL, et al: A
phase II study of the dual mTOR inhibitor MLN0128 in patients with
metastatic castration resistant prostate cancer. Invest New Drugs.
36:458–467. 2018.PubMed/NCBI View Article : Google Scholar
|
|
134
|
Kemp Bohan PM, Cindass JL, Chick RC,
Vreeland TJ, Hale DF, Hickerson A, Clifton GT, Peoples GE and Liss
M: Results of a phase Ib trial of encapsulated rapamycin in
prostate cancer patients under active surveillance to prevent
progression. J Clin Oncol. 38(34)2020.PubMed/NCBI View Article : Google Scholar
|
|
135
|
Narayan V, Vapiwala N, Subramanian P,
Christodouleas JP, Bekelman JE, Mick R, Walicki M, Ciconte J,
Rajendran RR and Haas NB: Phase I trial of everolimus plus
radiation therapy for salvage treatment of biochemical recurrence
in prostate cancer patients following prostatectomy. J Clin Oncol.
34(16617)2016.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Sweeney CJ, Percent IJ, Babu S, Cultrera
JL, Mehlhaff BA, Goodman OB, Morris DS, Schnadig ID, Albany C,
Shore ND, et al: Phase Ib/II study of enzalutamide with samotolisib
(LY3023414) or placebo in patients with metastatic
Castration-resistant prostate cancer. Clin Cancer Res. 28:2237–224.
2022.PubMed/NCBI View Article : Google Scholar
|
|
137
|
Courtney KD, Manola JB, Elfiky AA, Ross R,
Oh WK, Yap JT, Van den Abbeele AD, Ryan CW, Beer TM, Loda M, et al:
A phase I study of everolimus and docetaxel in patients with
castration-resistant prostate cancer. Clin Genitourin Cancer.
13:113–123. 2015.PubMed/NCBI View Article : Google Scholar
|
|
138
|
Chow H, Ghosh PM, deVere White R, Evans
CP, Dall'Era MA, Yap SA, Li Y, Beckett LA, Lara PN Jr and Pan CX: A
phase 2 clinical trial of everolimus plus bicalutamide for
castration-resistant prostate cancer. Cancer. 122:1897–1904.
2016.PubMed/NCBI View Article : Google Scholar
|
|
139
|
Vaishampayan U, Shevrin D, Stein M,
Heilbrun L, Land S, Stark K, Li J, Dickow B, Heath E and Smith D:
Phase II trial of carboplatin, everolimus, and prednisone in
metastatic castration-resistant prostate cancer pretreated with
docetaxel chemotherapy: A prostate cancer clinical trial consortium
study. Urology. 86:1206–1211. 2015.PubMed/NCBI View Article : Google Scholar
|
|
140
|
Rathkopf DE, Slovin SF, Morris MJ, Danila
DC, Delacruz A, Shelkey G, DeNunzio M, McLaughlin B and Scher H:
Targeting reciprocal feedback inhibition: Apalutamide and
everolimus in patients with metastatic castration-resistant
prostate cancer (mCRPC). J Clin Oncol. 15(204)2017.
|
|
141
|
Coleman N, Moyers JT, Harbery A, Vivanco I
and Yap TA: Clinical development of AKT inhibitors and associated
predictive biomarkers to guide patient treatment in cancer
medicine. Pharmgenomics Pers Med. 14:1517–1535. 2021.PubMed/NCBI View Article : Google Scholar
|
|
142
|
Lockney NA, Henderson RH, Swarts SG, Zhang
Z, Zhang B, Li J, Zlotecki RA, Morris CG, Casey-Sawicki KA and
Okunieff PG: Measuring radiation toxicity using circulating
Cell-free DNA in prostate cancer patients. Int J Part Ther.
8:28–35. 2022.PubMed/NCBI View Article : Google Scholar
|
